

28th January 2021

Southern Health and Social Care Trust

FOI Response 368

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Baricitinib [Olumiant]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]

Cimzia (Certolizumab)	65
Cosentyx (Secukinumab)	94
Enbrel (Etanercept)	25
Etanercept Biosimilars	163
Humira (Adalimumab)	47
Adalimumab Biosimilars	337
Jyseleca (Filgotinib)	0
Kevzara (Sarilumab)	<5
MabThera (Rituximab)	42
Olumiant (Baricitinib)	35
Orencia (Abatacept)	58



Otezla (Apremilast)	0
Remicade (Infliximab)	<5
Remsima (Infliximab)	26
Rituximab Biosimilars	113
Rinvoq (Upadacitinib)	0
RoActemra (Tocilizumab)	27
Simponi (Golimumab)	92
Stelara (Ustekinumab)	<5
Taltz (Ixekezumab)	<5
Xeljanz (Tofacitinib)	24

Q2. Could you please provide the numbers of patients treated for Ankylosing Spondylitis in the last 3 months with the following drugs. (Please only include patients where there is radiographic damage on X-ray of sacroiliac joints)

- Adalimumab [Humira]
- Adalimumab Biosimilars
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Golimumab [Simponi]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekezumab [Taltz]
- Secukinumab [Cosentyx]

This is not an accurate answer to this question as we do not keep information that detailed, only diagnosis of Ank Spond.

Ank Spond	Cimzia (Certolizumab)	10
	Cosentyx (Secukinumab)	37
	Enbrel (Etanercept)	6
	Etanercept Biosimilars	19
	Humira (Adalimumab)	16
	Adalimumab Biosimilars	98
	Remicade (Infliximab)	0
	Remsima (Infliximab)	7
	Simponi (Golimumab)	31
	Taltz (Ixekezumab)	0

Q3. Please could you provide the total number of patients treated with any biologic drug in the past 3 months who are diagnosed with the following:

- Ankylosing spondylitis (i.e. with radiographic damage on X-ray of sacroiliac joints)
- Non-radiographic axial spondyloarthritis (i.e. without radiographic damage on X-ray of sacroiliac joints)

As above and no other biologics used other than those listed in Q2

Ank Spond	Cimzia (Certolizumab)	10
	Cosentyx (Secukinumab)	37
	Enbrel (Etanercept)	6
	Etanercept Biosimilars	19
	Humira (Adalimumab)	16
	Adalimumab Biosimilars	98
	Remicade (Infliximab)	0
	Remsima (Infliximab)	7
	Simponi (Golimumab)	31
	Taltz (Ixekizumab)	0

The Trust has a legal duty to protect patient confidentiality, in line with this duty the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Contact: FOI.team@southerntrust.hscni.net